Stephen Hoge and Dean Li, at the STAT Summit, spoke of how Merck and Moderna will pair Keytruda with personalized mRNA vaccines to target tumors. ethics diagnostics Medical devices Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Saved Stories Billing Log Out Reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ Midterms 2026 Search Log In Try STAT+ My Account My Account Settings Saved Stories Billing History Home Matthew Herper spoke with…
After public school teacher Gary Keblish was diagnosed with melanoma in 2019, a surgeon cut out the tumor. But he wasn’t out of the woods. In some patients, melanoma aggressively recurs after surgery, so his doctors referred him to a new trial: for Merck and Moderna’s personalized mRNA cancer vaccine.
Speaking by video at the STAT Summit on Thursday, Keblish compared the journey — in all its physical and emotional turbulence — to a trip on Ms. Frizzle’s Magic School Bus. “Seatbelts, everyone!” he said, quoting the iconic line.
Read the rest…
US Pharma Marketing